THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Quintiles Transnational Corporation (Retired) (QTRN.X)

In 2002, Dr. Gillings provided extensive business-related travel services for himself and other Company employees with the use of his own plane. The Company reimbursed Dr. Gillings for the use of his plane by cash payments totaling approximately $1.4 million and by granting options to Dr. Gillings with an annual aggregate Black-Scholes value of approximately $1.4 million granted on a quarterly basis at an exercise price of $17.75 on March 31; $13.09 on June 15; $9.76 on September 16; and $12.11 on December 16. This reimbursement package was approved by the Human Resources and Compensation Committee.

On April 10, 2003, the Company entered into a merger agreement with Pharma Services and its wholly owned subsidiary, Pharma Services Acquisition Corp., pursuant to which Pharma Services Acquisition Corp. will be merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Pharma Services. Pharma Services was founded by Dr. Gillings and One Equity Partners LLC, the private equity arm of Bank One Corporation.

Dr. Geoffrey Barker, the husband of the Company's Chief Executive Officer, is the Company's Chief Medical and Scientific Officer and reports to the Company's Chairman. In connection with his employment, the Company pays him an annual salary of $225,000. The Company granted Dr. Barker options to purchase 1,552 shares of Common Stock at an exercise price of $17.75 per share on March 31, 2002; 4,812 shares of Common Stock at an exercise price of $13.09 on June 15, 2002; 6,701 shares of Common Stock at an exercise price of $9.76 on September 16, 2002; and 5,343 shares of Common Stock at an exercise price of $12.11 on December 16, 2002. The Company affords Dr. Barker customary employee benefits.

On January 1, 2001, the Company entered into a new consulting agreement with A.M. Pappas & Associates, LLC, or AMP&A, which superseded the consulting agreement dated January 1, 2000. The 2001 consulting agreement requires the Company to pay AMP&A specified fees for each day of services provided by AMP&A under the agreement. The Company has agreed to reimburse AMP&A for all reasonable out-of-pocket and administrative expenses incurred by AMP&A in connection with performing its services. In 2002, the Company paid AMP&A consulting fees of approximately $171,500 in cash and reimbursed AMP&A for approximately $3,050 in expenses pursuant to the consulting agreement entered into with AMP&A in January 2001. The Company terminated the January 1, 2001 consulting agreement in January 2003.

The Company is a limited partner in A. M. Pappas Life Science Ventures I, LP (formerly TechAMP International, L.P.) and A. M. Pappas Life Science Ventures II, LP (formerly A. M. Pappas TechAMP II, L.P.), funds organized to make venture capital investments in the equity securities of private companies in the life science sector. A. M. Pappas Life Science Ventures I and A. M. Pappas Life Science Ventures II are managed by their general partner, AMP&A Management, LLC and AMP&A Management II, LLC, respectively, affiliates of AMP&A. The Company has committed to invest an aggregate of $18.0 million in A. M. Pappas Life Science Ventures I and A. M. Pappas Life Science Ventures II. As a limited partner, the Company will make capital contributions under this commitment from time to time at the request of the fund's general partner. In 2002, the Company made capital contributions of $800,000 to A. M. Pappas Life Science Ventures I and $2.1 million to A. M. Pappas Life Science Ventures II.